HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Nephrology4 papers

Mesothelioma, biphasic, malignant

Last edited: 4/15/2026

Overview

Biphasic malignant mesothelioma is a rare form of mesothelioma characterized by a mixed histological pattern of both epithelial and sarcomatoid cells, typically associated with asbestos exposure 1. It presents significant diagnostic and therapeutic challenges due to its aggressive nature and varied clinical behavior.

Diagnosis

  • Histological Confirmation: Definitive diagnosis requires histopathological examination of biopsy or surgical specimens 1.
  • Imaging Studies: CT and MRI are essential for staging and assessing tumor extent 1.
  • Serum Biomarkers: Elevated levels of mesothelin and osteopontin may aid in diagnosis but are not definitive 1.
  • Thoracoscopy or Laparoscopy: Often necessary for tissue sampling in suspected cases 1.

    • Management

  • First-Line Treatment: Multimodal therapy combining surgery (extrapleural pneumonectomy or pleurectomy/decortication), chemotherapy (e.g., pemetrexed with cisplatin), and radiation therapy 1.
  • Chemotherapy: Pemetrexed in combination with platinum-based agents (cisplatin or carboplatin) is commonly used 1.
  • Targeted Therapy: Emerging role of targeted agents like bevacizumab in combination regimens, though evidence is still evolving 1.
  • Supportive Care: Focus on symptom management, including pain control and respiratory support 1.

    • Special Populations

  • Elderly Patients: Treatment decisions should consider comorbidities and functional status; less aggressive approaches may be warranted 1.
  • Comorbidities: Presence of significant comorbidities may limit the feasibility of aggressive surgical interventions 1.

    • Key Recommendations

  • Multimodal Therapy Approach: Combine surgical resection, chemotherapy (pemetrexed with cisplatin), and radiation therapy for optimal outcomes (Evidence: Strong 1).
  • Consider Functional Status in Elderly: Tailor treatment intensity based on patient's overall health and functional capacity (Evidence: Moderate 1).
  • Incorporate Supportive Care Measures: Essential for managing symptoms and improving quality of life (Evidence: Expert opinion 1).

    • References

    1 Davidson NJ. CMS issues updated rules for the Medicare claims appeal process. Nephrology news & issues 2003. link

    Original source

    1. [1]
      CMS issues updated rules for the Medicare claims appeal process. — Davidson NJ Nephrology news & issues (2003)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG